Neuroendocrine

Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab in Patients with Poorly Differentiated Extrapulmonay Small Cell Neuroendocrine Carcinomas

Protocol: SWOG – S2012 SCHEMA S2012 Please Note: Below is partial eligibility, for full eligible requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank  you! Eligibility: Participants must have histologically-confirmed (local site pathological confirmation sufficient) extrapulmonary poorly differentiated, small cell neuroendocrine carcinoma that is metastatic. Participants must have radiologically […]

A Prospective, Multi-Institutional Phase II Evaluating Temozolomide Vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma

Protocol – Alliance – A021804 SCHEMA A021804 Please Note – Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you! Eligibility: Histologically-proven advanced (metastatic or unresectable primary) pheochromocytoma or paraganglioma. Advanced (metastatic or unresectable primary) disease. Histologically-proven pheochromocytoma or paraganglioma. Radiographic evidence […]